Healio18h
FDA grants priority review to oral non-small cell lung cancer drug
The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...
precisionmedicineonline1d
Dizal Pharmaceutical Seeking FDA Approval for Sunvozertinib in EGFR Exon 20 Insertion-Mutated NSCLC
Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.
oncnursingnews3d
Dordaviprone Seeks FDA Approval for Recurrent H3K27M+ Diffuse Glioma
A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.
Cure Today4d
FDA Reviews NDA for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...
Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)
Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock ...
FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...